Unknown PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT04384588

COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID) (FALP-COVID)

Investigational- Compassionate Use of Convalescent Plasma From COVID-19 Donors in Oncological and Non-Oncological Patients With Severity Criteria: FALP 001-2020 Trial (FALP-COVID)

Sponsor: Bolsa de Santiago

Conditions COVID-19 Infection Cancer Patients General Population

Interventions Convalescent Plasma from COVID-19 donors

Updated 5 times since 2020 Last updated: May 9, 2020 Started: Apr 7, 2020 Primary completion: Apr 6, 2021 Completion: Apr 6, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on COVID-19 Infection and Cancer Patients, this trial is ongoing. The trial is conducted by Bolsa de Santiago and has accumulated 5 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jun 2022 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3

Status: Recruiting → Unknown Status
Jan 2021 — Jun 2022 [monthly]

Recruiting PHASE2_PHASE3
Jun 2020 — Jan 2021 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Apr 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bolsa de Santiago
Confederación de la Producción y del Comercio (CPC)
Fundacion Arturo Lopez Perez

Data source: Fundacion Arturo Lopez Perez

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Providencia, Chile